Linked Life Data

10897579

Source:http://linkedlifedata.com/resource/pubmed/id/10897579

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2000-10-2
pubmed:abstractText
Luteinizing hormone-releasing hormone (LHRH) agonists are popularly used drugs in the treatment of prostatic cancer. However, it has been reported that continuation of a low testosterone level following a longterm administration of these drugs reduces the bone mineral density and makes for osteoporosis, which is accountable for fracture, we measured the bone mineral density and bone metabolic markers in the cases who suffered fracture receiving LHRH agonists for prostatic cancer.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0021-5287
pubmed:author
pubmed:issnType
Print
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
542-6
pubmed:dateRevised
2011-7-28
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
[Bone fracture receiving LH-RH agonists for prostatic cancer].
pubmed:affiliation
Department of Urology, Jikei University School of Medicine.
pubmed:publicationType
Journal Article, English Abstract